Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
Primary Purpose
Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2, Very Long Chain Acyl Coa Dehydrogenase Deficiency
Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Nutritional Ketone Supplement
Isocaloric Placebo Supplement
Sponsored by
About this trial
This is an interventional other trial for Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Eligibility Criteria
Inclusion Criteria:
- confirmed diagnosis of VLCAD, LCHAD/TFP or CPT2 deficiency
- speak English
- willing to complete 2 moderate intensity exercise treadmills
Exclusion Criteria:
- subjects actively participating in another research study that prohibits their participation
- pregnant females
- subjects with diabetes or taking medications to treat diabetes
Sites / Locations
- Oregon Health & Science UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Nutrition Ketogenic Supplement
Isocaloric Placebo Supplement
Arm Description
The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.
The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.
Outcomes
Primary Outcome Measures
Adverse Events- incidence
Number of Adverse events
Adverse Events- type
Description of Adverse events: categorical
Adverse Events- severity
Severity of adverse event: grade 1-5
Adverse Events- causal relationship
Yes/No related to product intake
Abdominal discomfort
visual analogue scale (VAS) 0-10
Decreased appetite
visual analogue scale (VAS) 0-10
Gastric reflux
visual analogue scale (VAS) 0-10
Nausea
visual analogue scale (VAS) 0-10
Diarrhea
visual analogue scale (VAS) 0-10
Headache
visual analogue scale (VAS) 0-10
Secondary Outcome Measures
Blood Ketones
plasma beta-hydroxybutyrate concentration
Blood Creatine Kinase
plasma CK concentration
Blood Glucose
serum glucose
Blood Lactate
serum lactate concentration
Blood Pressure
diastolic BP
Blood Pressure
systolic BP
Perceived exertion
Borg scale 1-20
Respiratory Exchange Ratio
VCO2/VO2 0.7 - 1.0
Heart Rate
beats per minute
Full Information
NCT ID
NCT05411835
First Posted
May 27, 2022
Last Updated
October 3, 2022
Sponsor
Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT05411835
Brief Title
Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
Official Title
Safety and Tolerability of Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
July 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to determine if an oral ketone beverage is safe and well-tolerated during moderate intensity exercise in participants with long-chain fatty acid oxidation disorders and if it will raise blood ketones to levels similar to that reported among normal healthy subjects.
Detailed Description
Purpose: Subjects with long-chain fatty acid oxidation disorders (LC-FAOD) do not make ketones during fasting or with exercise. Ketones are an important alternative energy substrate during moderate exercise, sparing the oxidation of glucose and providing a source of ATP to the central nervous system and exercising muscle. Fatty acid oxidation in the liver is required to make ketones. Subjects with a LC-FAOD cannot generate ketones because of their block in fatty acid oxidation during exercise. Providing ketones in an oral ketone beverage may increase blood ketones with exercise to levels normally observed in humans.
Aim: To determine the safety and tolerability of an oral ketone beverage during moderate intensity exercise among subjects with a LC-FAOD compared to an isocaloric maltodextrin beverage, and to determine blood ketone concentrations.
Hypothesis: Oral consumption of a ketone beverage before moderate intensity exercise will be safe and well-tolerated, and will raise blood ketones among subjects with a LC-FAOD to concentrations similar to that reported in the literature among normal healthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Carnitine Palmitoyltransferase Deficiency 2, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Trifunctional Protein Deficiency
7. Study Design
Primary Purpose
Other
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Subjects with either CPT2, TFP, LCHAD or VLCAD deficiency will be randomized to receive a ketone beverage (see composition in Appendix A) or an isocaloric maltodextrin control beverage (see composition in Appendix A) before moderate intensity exercise. Twenty minutes after consuming the pre-exercise beverage, subjects will complete a moderate intensity treadmill exercise test for 45 minutes. After a washout period of 48 hours, subjects will repeat the exercise. During the 2nd exercise test subjects will crossover to the beverage not consumed during the 1st exercise study.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Sachets of the ketone or maltodextrin powder are coded and packaged identically. The bionutrition unit will prepare the beverage and maintain the randomization code and the code for the ketone and maltodextrin products.
Allocation
Randomized
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nutrition Ketogenic Supplement
Arm Type
Active Comparator
Arm Description
The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.
Arm Title
Isocaloric Placebo Supplement
Arm Type
Sham Comparator
Arm Description
The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.
Intervention Type
Dietary Supplement
Intervention Name(s)
Nutritional Ketone Supplement
Other Intervention Name(s)
NKS
Intervention Description
Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
Intervention Type
Dietary Supplement
Intervention Name(s)
Isocaloric Placebo Supplement
Intervention Description
Maltodextrin with flavors and stevia sweetener
Primary Outcome Measure Information:
Title
Adverse Events- incidence
Description
Number of Adverse events
Time Frame
2 hours after product intake
Title
Adverse Events- type
Description
Description of Adverse events: categorical
Time Frame
2 hours after product intake
Title
Adverse Events- severity
Description
Severity of adverse event: grade 1-5
Time Frame
2 hours after product intake
Title
Adverse Events- causal relationship
Description
Yes/No related to product intake
Time Frame
2 hours after product intake
Title
Abdominal discomfort
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Title
Decreased appetite
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Title
Gastric reflux
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Title
Nausea
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Title
Diarrhea
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Title
Headache
Description
visual analogue scale (VAS) 0-10
Time Frame
2 hours after product intake
Secondary Outcome Measure Information:
Title
Blood Ketones
Description
plasma beta-hydroxybutyrate concentration
Time Frame
20 minutes after moderate intensity exercise
Title
Blood Creatine Kinase
Description
plasma CK concentration
Time Frame
20 minutes after moderate intensity exercise
Title
Blood Glucose
Description
serum glucose
Time Frame
20 minutes after moderate intensity exercise
Title
Blood Lactate
Description
serum lactate concentration
Time Frame
20 minutes after moderate intensity exercise
Title
Blood Pressure
Description
diastolic BP
Time Frame
peak 40 minute exercise
Title
Blood Pressure
Description
systolic BP
Time Frame
peak 40 minute exercise
Title
Perceived exertion
Description
Borg scale 1-20
Time Frame
peak 40 minute exercise
Title
Respiratory Exchange Ratio
Description
VCO2/VO2 0.7 - 1.0
Time Frame
peak 40 minute exercise
Title
Heart Rate
Description
beats per minute
Time Frame
peak 40 minute exercise
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
confirmed diagnosis of VLCAD, LCHAD/TFP or CPT2 deficiency
speak English
willing to complete 2 moderate intensity exercise treadmills
Exclusion Criteria:
subjects actively participating in another research study that prohibits their participation
pregnant females
subjects with diabetes or taking medications to treat diabetes
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ashley Gregor, MS
Phone
503-494-5313
Email
gergora@ohsu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melanie B Gillingham, PhD
Phone
503-494-1682
Email
gillingm@ohsu.edu
Facility Information:
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Gregor, MS
Phone
503-494-5313
Email
gregora@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Melanie Gillingham, PhD
Phone
503-494-1682
Email
gillingm@ohsu.edu
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Participants will be provided with creatine kinase lab test and body composition measurement. The results of their creatine kinase lab test will be placed in their medical record. Results of the study will be written in a published manuscript and summarized in a cover letter to be sent via mail or email to the participant after publication of the data.
IPD Sharing Time Frame
The published manuscript will be available approximately 6-9 months after the conclusion of the study.
IPD Sharing Access Criteria
not applicable. A reprint will be sent to participants.
Learn more about this trial
Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
We'll reach out to this number within 24 hrs